Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-AblT315I mutant. Issue 17 (1st September 2015)

• Record Type: Journal Article
• Authors: Lu, Xiaoyun; Zhang, Zhang; Ren, Xiaomei; Pan, Xiaofeng; Wang, Deping; Zhuang, Xiaoxi; Luo, Jingfeng; Yu, Rongmin; Ding, Ke
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 25:Issue 17(2015)
• Page Start: 3458
• Page End: 3463
• Publication Date: 2015-09-01
• Subjects: Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2015.07.006
• Languages: English
• ISSNs: 0960-894X

Abstract

<abstract xml:lang="en" abstract-type="graphical" id="ab005"> <title id="st015">Graphical abstract</title> <sec> <p id="sp0005">A series of pyrimidine alkynyl derivatives were designed and synthesized as new Bcr-Abl inhibitors by hybriding the structural moieties from GNF-7, ponatinib and nilotinib. Compound <bold>4e</bold> is one of the most potent compounds. <fig id="f0045" position="anchor"><graphic position="anchor" xlink:href="ark:/27927/pgj28j8q2sd" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink" /></fig></p> </sec> </abstract>